Clinical trials: Conventional therapy
Patent Foramen Ovale, Stroke
PFO ACCESS Registry
Closure of Patent Foramen Ovale with the AMPLATZER® PFO OCCLUDER in patients with at least two cryptogenic strokes due to presumed paradoxical embolism through a patent foramen ovale and who have failed conventional therapy.
- Trial name
- NCT00583401
- Testing
- Device closure with the AMPLATZER PFO Occluder
- Sponsor
- Abbott Medical Devices
Asthma
Asthma Intervention Research (AIR) Trial
The purpose of this study is to demonstrate the effectiveness and safety of the Alair System for the treatment of asthma. This will be a multicenter, randomized controlled study comparing the effects of treatment with the Alair…
- Trial name
- NCT00214526
- Testing
- Bronchial thermoplasty with the Alair System, Conventional therapy with ICS+LABA
- Volunteers
- 112 people
- Sponsor
- Asthmatx, Inc.
Head and Neck Cancers, Breast Cancer
Feasibility Study of CBCT for IGRT in Cancer Patients
Cone beam computed tomography (CBCT) is an imaging technology that is incorporated into many modern radiation therapy systems. The quality of conventional CBCT is good enough to align patients for their daily radiation therapy…
- Conditions
- Head and Neck Cancers, Breast Cancer, Thoracic Cancers, Liver Cancer
- Trial name
- NCT06681233
- Testing
- Comparison of HyperSight CBCT imaging to conventional CBCT imaging.
- Where
- 4 sites in United States
- Volunteers
- 50 people
- Sponsor
- Varian, a Siemens Healthineers Company
HER2-positive Advanced Gastric Cancer, HER2-positive Gastroesophageal Junction Adenocarcinoma
A Study of Trastuzumab DeRuxtecan for Patients With Advanced HER2-pOsitive GaStric or GastroesoPhageal Junction AdEnocarcinoma Who Have Received a PrIor Trastuzumab-based Regimen Accompanied by a Disease RegistrY of Patients Treated With Conventional Therapies (PROSPERITY)
Trastuzumab deruxtecan (T-DXD) as monotherapy is indicated for the treatment of adult patients with advanced HER2-positive advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma who have received a prior…
- Trial name
- NCT05993234
- Testing
- Trastuzumab deruxtecan
- Where
- 39 sites in Austria, Belgium and 2 more
- Volunteers
- 257 people
- Sponsor
- Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company
Advanced Solid Tumor Malignancies
HX044,FIH Study in Patients with Advanced Solid Tumor Malignancies
The study will consist of a dose-escalation and dose-expansion component to establish the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D), and to evaluate the preliminary antitumor activity of HX044.
- Trial name
- NCT06649708
- Testing
- HX044
- Where
- 3 sites in Australia
- Volunteers
- 100 people
- Sponsor
- Hanx Biopharmaceuticals (Wuhan) Co., Ltd.
End-Stage Renal Disease
Cook Enforcer Post-Market Study
The purpose of this study is to evaluate the performance of the Cook Advance® Enforcer™ 35 Focal-Force PTA Balloon Catheter (or Enforcer balloon) in treating narrowed blood vessels compared to treatment with a conventional…
- Trial name
- NCT03552289
- Testing
- Cook Advance® Enforcer 35 Focal-Force Percutaneous Transluminal Angioplasty (PTA) Balloon Catheter, Conventional angioplasty balloon catheters
- Where
- 5 sites in United States
- Volunteers
- 211 people
- Sponsor
- Cook Research Incorporated
Cancer, Metastatic Castration-resistant Prostate Cancer
Study of INKmune in Patients With mCRPC (CaRe Prostate)
This is an open-label, phase I/IIa dose escalation and expansion study of INKmune in men with mCRPC. INKmune is administered to patients intravenously over three doses, at least one-week apart.
- Conditions
- Cancer, Metastatic Castration-resistant Prostate Cancer, mCRPC
- Trial name
- CaRe (NCT06056791)
- Testing
- INKmune
- Where
- 8 sites in United States
- Volunteers
- 12 people
- Sponsor
- Inmune Bio, Inc.
NSCLC (Advanced Non-small Cell Lung Cancer)
A Study of BH-30643 in Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations
This Phase1/2, open label, multicenter study will assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics and preliminary anti-tumor activity of BH-30643 in patients with NSCLC having EGFR and/or HER2 mutations.
- Trial name
- SOLARA (NCT06706076)
- Testing
- BH-30643, BH-30643 combo therapy with Carboplatin/Pemetrexed
- Where
- 42 sites in United States, Australia and 7 more
- Volunteers
- 675 people
- Sponsor
- BlossomHill Therapeutics
General Anxiety Disorder
Clinical Trial to Evaluate the Efficacy and Safety of the Aurora® Digital Medical Device in Adult Patients With Moderate to Severe Generalized Anxiety Disorder
To evaluate the superiority of cognitive behavioral therapy using the Aurora® digital medical device + conventional drug treatment, compared to conventional drug treatment alone, in reducing anxiety symptoms, as assessed by the…
- Trial name
- NCT07477990
- Testing
- App AURORA (Digital Therapy) + conventional treatment, Pharmacological conventional treatment
- Where
- Mexico
- Volunteers
- 162 people
- Sponsor
- Psicofarma, S.A. De C.V.
Upper Gastrointestinal Bleeding
UI-EWD for Endoscopic Hemostasis of Bleeding Peptic Ulcers and Bleeding After EMR/ESD
UI-EWD (NextBiomedical Co, Incheon, South Korea), a new hemostatic powder for endoscopic treatment of high-risk bleeding peptic ulcers and bleeding after ESD/EMR.
- Trial name
- NCT02978391
- Testing
- UI-EWD Hemostatic system, epinephrine endoscopic injection (conventional therapy)
- Where
- 2 sites in South Korea
- Volunteers
- 76 people
- Sponsor
- Next Biomedical Co., Ltd.
Stroke
The Effectiveness of Occupation-based Bilateral Arm Training on Motor Functions and Activity Participation Among Stroke Survivors During Inpatient Rehabilitation.
People with stroke often experience limitations in motor functions and activity participation. Occupation-based bilateral upper limb training (OBBT) using occupations as meaningful daily activities, and as part of the therapy.
- Trial name
- NCT07164612
- Testing
- Occupation-Based Bilateral Upper Limb Training (OBBT), Conventional therapy group
- Where
- Qatar
- Volunteers
- 150 people
- Sponsor
- Hamad Medical Corporation
Rheumatoid Arthritis
A Moderate to Severe Rheumatoid Arthritis Study
The purpose of this study is to determine whether baricitinib 4 milligram (mg) once daily is superior to placebo in the treatment of participants with moderately to severely active Rheumatoid Arthritis (RA) who have had an…
- Trial name
- RA-BEACON (NCT01721044)
- Testing
- Baricitinib, cDMARD
- Where
- 103 sites in United States, Argentina and 20 more
- Volunteers
- 527 people
- Sponsor
- Eli Lilly and Company
Acute-On-Chronic Liver Failure
Efficacy and Safety of BMSCs (CG-BM1) for ACLF Patients
The goal of this clinical trial is to learn if CG-BM1 Allogeneic Human Bone Marrow Mesenchymal Stem Cell Injection (hereinafter referred to as CG-BM1) can treat acute-on-chronic liver failure (ACLF) patients.
- Trial name
- NCT06740149
- Testing
- Bone marrow mesenchymal stem cells (low dose), Solvent of CG-BM1, Bone marrow mesenchymal stem cells (medium dose)
- Where
- China
- Volunteers
- 100 people
- Sponsor
- GuangZhou Cellgenes Biotechnology Co., Ltd.
Correction of Nasolabial Folds
Observational Study to Evaluate Long-term Safety and Biodegradability of YVOIRE Classic s
To evaluate long-term safety of YVOIRE classic s by incidence of adverse events including injection site local reactions and biodegradability
- Trial name
- NCT02334358
- Testing
- YVOIRE Classic s
- Where
- China
- Volunteers
- 503 people, healthy volunteers welcome
- Sponsor
- LG Life Sciences
Asthma
A Comparison of Symbicort® Single Inhaler Therapy and Conventional Best Practice for the Treatment of Persistent Asthma
The primary objective is to compare the efficacy of Symbicort Single inhaler Therapy with treatment according to conventional best practice in adult patients with persistent asthma.
- Trial name
- PASSION (NCT00628758)
- Testing
- Symbicort TBH - Turbuhaler, beta-II-agonist, inhale steroid
- Where
- 15 sites in Turkey (Türkiye)
- Volunteers
- 430 people
- Sponsor
- AstraZeneca
Paroxysmal Atrial Fibrillation
Treatment of PAF With the Synaptic System
Enrolled subjects will be treated with the Synaptic Cryoablation System. Treatment will include cryoablation of the pulmonary veins to achieve PVI.
- Trial name
- Sensation (NCT05905835)
- Testing
- Synaptic Cryoablation System
- Where
- 10 sites in United States
- Volunteers
- 128 people
- Sponsor
- Synaptic Medical Corporation
Lower Urinary Tract Symptoms (LUTS) Associated With Benign Prostatic Hyperplasia (BPH)
A Study to Evaluate the Tolerability and Efficacy of Tamsulosin 0.4mg OCAS Formulation in Patients Who Are Unsatisfied With the Treatment of Tamsulosin 0.2mg Conventional Formulation
This is an open-label, single-arm, prospective interventional study to assess the tolerability and efficacy of Harnalidge® OCAS® 0.4 mg in Taiwan patients who are unsatisfied with tamsulosin 0.2 mg for the treatment of lower…
- Trial name
- NCT02180789
- Testing
- Tamsulosin OCAS
- Where
- Taiwan
- Volunteers
- 100 people
- Sponsor
- Astellas Pharma Inc
Hodgkins Lymphoma
Avelumab In Patients With Previously Treated Advanced Stage Classical Hodgkin's Lymphoma (JAVELIN HODGKINS)
This is a Phase 1b, open-label, multi-center study comprising a lead-in phase and an expansion phase. The lead-in phase is a multiple-dose, randomized, parallel-arm, pharmacokinetic and pharmacodynamic study of avelumab as a…
- Trial name
- NCT02603419
- Testing
- Avelumab
- Where
- 13 sites in United States, Italy and 1 more
- Volunteers
- 34 people
- Sponsor
- Pfizer
Arthritis, Rheumatoid
Subcutaneous Golimumab (GLM) Plus DMARDs for Rheumatoid Arthritis, Followed by Intravenous/Subcutaneous GLM Strategy (P06129 AM2)
Part 1 of this trial will assess the safety and effectiveness of subcutaneous (SC) golimumab administered by autoinjector once monthly, when combined with different disease-modifying antirheumatic drug (DMARD) regimens used in…
- Trial name
- GO-MORE (NCT00975130)
- Testing
- SC golimumab, IV golimumab
- Volunteers
- 3,366 people
- Sponsor
- Merck Sharp & Dohme LLC
Congenital Adrenal Hyperplasia
A Study to Determine Eligibility for CAH-301 (A Study of Gene Therapy for Classic Congenital Adrenal Hyperplasia (CAH) [NCT04783181])
This pre-screening study is designed to determine potential eligibility of adults with classic CAH due to 21-hydroxylase deficiency (21-OHD) for participation in the CAH-301 [NCT04783181] gene therapy trial with BBP-631.
- Trial name
- NCT05101902
- Testing
- Pre-Screening
- Where
- United States
- Volunteers
- 65 people
- Sponsor
- Adrenas Therapeutics Inc